5 MIN PRESENTATION
Press about us
TRY OUR OLD WEBSITE
Artificial Intelligence for Drug Discovery and Aging Research
We provide services to academia, pharmaceutical and cosmetics companies:
Advanced deep learning solutions
Custom drug discovery engines
Custom biomarkers discovery
New tools for aging research
We license 827 drug-disease predictions and biomarkers:
573 antineoplastic agents
114 metabolic regulators
41 CVD disease candidates
38 CNS agents
37 anti-cancer immune response boosters
Aging biomarkers (biochemical and transcriptional)
Cancer biomarkers (biochemical and transcriptional)
Our Mission is to Extend Healthy Longevity
Awards & Recognition
ACS Editors' Choice
Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data
Most Promising Company
at the Personalized Medicine World Conference 2015 in Palo Alto, CA
Nvidia GTC 2015 Finalist
Deep Learning for Drug Discovery
Nvidia Top 5
AI Companies for Social Impact
Some of Our Current Projects
Exclusive partnership with Life Extension
Videos about Insilico Medicine
Our YouTuBe channel
About Insilico Medicine
Basel Life Science Week: Practical Applications of Aging Research Forum
Embryonic AI: Analysis of Embryonic State using Deep Neural Networks (Property of Biotime, Inc)
Aging Researcher Insilico Medicine Takes Top Prize at PMWC 2015
Over 150 Academic and Industry Collaborators Worldwide
Taiwan DCB, PITDC, TMU and Insilico Medicine join forces
to apply AI for biomedical research
CHECK OUT OUR LATEST NEWS
Nvidia identifies the top 5 AI startups for social impact
These are Genetesis, Lunit, Insilico Medicine, SigTuple, and Bay Labs.
ALS.AI drug discovery platform
Insilico Medicine to use Artificial Intelligence platform to discover new Amyotrophic Lateral Sclerosis therapies.
The beauty of AI
Beiersdorf about AI for skin care research.
Billionaire investor to accelerate research in artificial intelligence in healthcare
Jim Mellon, who is famous for identifying major trends, has announced his commitment to support research in human longevity.
Artificial intelligence enters the nutraceutical industry
Life Extension and Insilico Medicine to launch the first natural geroprotector combination and start a new research collaboration.
Leading US and Korean researchers to apply artificial intelligence to aging research
Insilico Medicine partners with Gachon University and Gil Medical Center to apply AI to extend healthy human longevity.
In silico Pathway Activation Network Decomposition Analysis (iPANDA)
A novel approach for precision medicine and drug discovery on gene expression data.
Aging.AI 2.0 is available for testing
Comparing Aging.AI 1.0 using 41 blood biochemistry biomarkers, Aging.AI 2.0 uses just 33 parameters from the blood test and has slightly higher mean absolute error.
Collaboration with Life Extension on geroprotector development
Advances in computational biology and AI used to identify compounds with potential to extend human life.
Insilico Medicine and Biotime to develop Embryonic.AI
Insilico Medicine and ChemDiv to develop and market targeted panels of oncology compounds
Insilico Medicine and Life Extension form a partnership to develop aging biomarkers and geroprotectors
Insilico Medicine and Nazarbayev University start a collaboration to develop population-level biomarkers of aging
OUR LATEST PUBLICATION
The cornucopia of meaningful leads:
Applying deep adversarial autoencoders for new molecule development in oncology
Oncotarget, 22 December 2016
"The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology."
"A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation."
"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data."
"Applications of deep learning in biomedicine."
"Deep biomarkers of human aging: Application of deep neural networks to biomarker development."
"In search for geroprotectors: in silico screening and
validation of signalome-level mimetics of young healthy state."
Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development."
Alex Zhavoronkov, PhD
Qingsong Zhu, PhD
President of European Operations
Marine Bozdaganyan, PhD
Head of Medical Chemistry
Ivan Ozerov, PhD
Director, Drug Discovery
Quentin Vanhaelen, PhD
Director, Virtual Human Project
We have 39 scientists hired through hackathons and competitions worldwide in the US, Poland, Belgium, and Russia.
30% of our staff are women.
Scientific Advisory Board
Charles Cantor, PhD
ex-Director of the Human Genome Project and the Center for Advanced Biotechnology at Boston University
Michael Levitt, PhD
2013 Nobel Laureate (Chemistry) Professor, Stanford University
Bud Mishra, PhD
Professor of computer science at Courant Institute, professor of biology at Mt. Sinai School of Medicine and NYU School of Medicine
Donald Small, MD, PhD
Director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center
Yuri Nikolsky, PhD
ex-VP, Thomson Reuters
Director, Skolkovo Found
Kristen Fortney, PhD
Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Alexey Moskalev, PhD
Professor at Syktyvkar State University
Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
Ulrich Muehlner, PhD
Founder at GrowthCube Partners
Previously Director Global Corporate Strategy at Novartis and with The Boston Consulting Group (BCG)
Basel Life Science Week
Aging and Drug Discovery Forum
Artificial Intelligence for Drug Discovery and Biomarker Development
Chair: Alex Zhavoronkov
September 11-15, 2017
Artificial Intelligence Innovation Summit
San Francisco, USA
September 18-19, 2017
Press About Us
Insilico Medicine, Inc.
Emerging Technology Centers
Johns Hopkins University Eastern Campus
Suite B301, 1101 East 33rd St.
Baltimore, MD 21218
Phone: +1 443 451 7212
Fax: +1 443 451 7210
© 2016 All Right Reserved. Insilico Medicine, Inc.